Querida Anderson

The latest business and financial biotech news. In this issue: 1) Adherex Buys Back GSK's Rights to Failed Cancer Drug 2) Archemix and Merck Partner on Aptamer-Based Cancer Therapeutics 3) CEL-SCI Receives $15 Million Commitment for Cancer Drug Manufacturing Facility 4) Genentech and Seattle Genetics Ink Deal Potentially Worth $860 Million 5) Dana-Farber Cancer Institute Launches $1-Billion Campaign

News items reported in this issue: 1) 186-Gene Signature in Cancer Stem Cells Predicts Recurrence 2) National Prostate Cancer Coalition Commences Clinical Trial Education Program 3) Concomitant High-Dose Radiation Therapy Plus Cetuximab Improves Locoregional Control and Reduces Mortality, with No Increase in Radiation Therapy–Associated Toxicity in Patients with Advanced Squamous-Cell Carcinoma of the Head and Neck 4) STAT3 Pathway Inhibitor (Degrasyn) Drug Class Shows Promise in the Treatment of Malignant Brain Tumors

Physicians' Financial News focuses on news-making and/or notable companies in the oncology/biotechnology sector. In this issue: 1) Avalon Could Earn More Than $200M in Deal with Merck & Co. 2) OXiGENE Sets Fiscal 2007 Priorities 3) Genentech Shares Fall Nearly 3% on Avastin Study 4) Start-Up Biotech Firm VentiRx Acquires $26.6 Million in Venture Capital Financing to Develop New Cancer Drugs 5) Vion Reports Fourth Quarter Loss of $6.1 Million 6) Somanta Acquisition Enhances Access Pharmaceuticals Cancer Focus 7) Stemline In-Licenses Compound that Targets Leukemia Stem Cells

News reports featured in this issue: 1) Breast Cancer Spotlight 2) Expert Cancer Centers Cost-Effective for Managing Ovarian Cancer 3) New Breathalyzer "Smells" Lung Cancer in Early Stages 4) PSA Adjusted for Prostate Size is Possible Identifier of Men at Risk for Developing Life-Threatening Cancer

Physicians' Financial News focuses on news-making and/or notable companies in the oncology/biotech sector. In this issue: 1) Aveo Lands $477M Deal with Schering Plough 2) Eisai Grows Pharma-Based Cancer Pipeline in $325M Acquisition of Morphotek 3) Pharmacyclic and Genta Appeal FDA Decisions on NDAs 4) Oxford Biomedica Takes Over Oxxon Therapeutics for $31.6M 5) Micromet Could Earn $100M in Collaboration with Tracon 6) Yawkey Foundation Makes Second Largest Individual Donation to Dana-Farber $1B Campaign

The Clinical Trials reported in this issue include: PHASE I: 1) Adherex Initiates Combination Trial of ADH-1 and Melphalan for Melanoma Treatment 2) Erimos Initiates Evaluation of First-In-Class Small Molecule Therapy for Glioma Brain Tumors PHASE II: 1) ChemGenex Treats First Patient in CML Trial 2) Cleveland BioLabs Phase II Hormone-Refractory Prostate Cancer Trial Advances to Next Phase 3) Helix Shows Positive Results in Treatment of HPV-induced, Low-Grade Cervical Lesions PHASE III: 1) Amgen and ImClone's Competing EGFr-targeting Drugs Battle It Out in the Clinic

Physicians' Financial News focuses on news-making and/or notable companies in the oncology/biotech sector. In this issue: 1) Cell Therapeutics' Indolent NHL Agent Gets Fast Tracked 2) First Low-Molecular-Weight Heparin Approved for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer 3) ArQule Stands to Earn $123 Million in Deal with Kyowa 4) Dendreon's Prostate Cancer Immunotherapy Suffers Setback 5) Amgen Anemia Portfolio at Risk 6) Antisoma Could Gain $890 Million from Novartis Deal

The Clinical Trials reported in this issue are: PHASE I: CuraGen, TopoTarget Begin Study of HDAC Inhibitor Candidate as Combination Therapy for Soft Tissue Sarcomas Ambrilia's Therapeutic Peptide Shows Clinical Activity in Metastatic Prostate Cancer Patients PHASE II: Alchemia's Precursory Evaluation of mCRC Study Presents Positive Efficacy Data IsoRay's Cesium-131 Established as Front-Line Treatment for Early-Stage Prostate Cancer PHASE III: BDSI Closer to Filing NDA for Delivery Technology in Breakthrough Cancer Pain Market Tarceva Sees Continued Positive Clinical Data and Spurs Growth for OSI

Physicians' Financial News focuses on newsworthy and/or notable companies in the oncology/biotech sector. In this issue: 1) Amgen: Amgen Oncology Under Review 2) Myriad Genetics, Inc.: Launches Test to Predict Toxicity to 5-FU 3) GPC Biotech AG: Pulls NDA for Prostate Cancer Drug 4) Cell Therapeutics, Inc.: Pads Pipeline through $20-Million Acquisition of Systems Medicine 5) Veridex: FDA Approves First Gene-Based Test to Detect the Spread of Breast Cancer 6) Ariad Pharmaceuticals/Merck: Ariad Could Earn $727 Million in Deal with Merck Related to Its Novel mTOR Inhibitor

The Clinical Trials reported in this issue include: PHASE IV: Obesity a Major Risk Factor for Multiple Myeloma PHASE III: 1) Long-Term Safety of Adjuvant Trastuzumab (Herceptin) 2) Bevacizumab (Avastin) Helps Slow Tumor Growth in Patients with Advanced or Recurrent Non-Small-Cell Lung Cancer 3) Addition of Bevacizumab To Interferon Alfa 2a Nearly Doubles Median Progression-Free Survival in Patients with Previously Untreated Advanced Kidney Cancer 4) New Hope for the Treatment of Advanced Melanoma PHASE II: 1) Leukemia Treatment With Fludarabine Plus Cyclophosphamide 2) Refractory Soft Tissue Sarcoma Treatment PHASE I: Radiation-Induced Vision Loss Curtailed by Cancer Drug

Physicians' Financial News focuses on newsworthy and/or notable companies i the oncology/biotech sector. In this issue: 1) GlaxoSmithKline 2) Ventana Medical Systems Inc. and Roche Holding AG 3) Pfizer Inc. 4) Celgene Corporation 5) Coley Pharmaceutical Group, Inc.